Table 2.
Characteristics of study population by the number of gene variants.
| No. of gene variants
|
|||||
|---|---|---|---|---|---|
| Characteristic | Subjects with all three genotypes | 0 | 1 | 2 or 3 | Subjects excludeda |
| No. | 613 | 237 | 276 | 100 | 131 |
| Continuous variables (mean ± SD) | |||||
| Age (years) | 67.3 ± 7.2 | 67.6 ± 7.3 | 67.3 ± 7.2 | 66.6 ± 7.0 | 70.0 ± 7.3 |
| BMI (kg/m2 ) | 27.9 ± 3.7 | 28.0 ± 3.8 | 28.1 ± 3.6 | 27.2 ± 3.5 | 27.6 ± 4.5 |
| Albumin-adjusted serum calcium (mg/dL) | 9.0 ± 0.3 | 9.0 ± 0.3 | 9.0 ± 0.3 | 9.0 ± 0.4 | 9.1 ± 0.4 |
| Systolic blood pressure (mm Hg) | 137.1 ± 18.1 | 137.0 ± 18.5 | 136.9 ± 17.1 | 137.7 ± 20.0 | 137.0 ± 17.1 |
| Diastolic blood pressure (mm Hg) | 81.7 ± 9.7 | 81.7 ± 10.0 | 81.5 ± 9.5 | 82.4 ± 9.5 | 80.6 ± 9.5 |
| QTc interval (msec) | 395.7 ± 30.3 | 398.1 ± 31.7 | 393.3 ± 28.2 | 396.5 ± 32.3 | 400.2 ± 38.7 |
| Categorical variables [n (%)] | |||||
| Smoking status | |||||
| Never | 195 (31.8) | 67 (28.3) | 92 (33.3) | 36 (36.0) | 29 (22.1) |
| Former | 371 (60.5) | 151 (63.7) | 163 (59.1) | 57 (57.0) | 91 (69.5) |
| Current | 47 (7.7) | 19 (8.0) | 21 (7.6) | 7 (7.0) | 11 (8.4) |
| History of myocardial infarction | 29 (4.7) | 10 (4.2) | 14 (5.1) | 5 (5.0) | 12 (9.2) |
| Diabetes | 43 (7.0) | 14 (5.9) | 22 (8.0) | 7 (7.0) | 14 (10.7) |
| Hypertension | 266 (43.4) | 108 (45.6) | 111 (40.2) | 47 (47.0) | 53 (40.5) |
| Lead levels [median (IQR)] | |||||
| Tibia lead (μg/g) | 19 (14–27) | 19 (13–27) | 20 (14–28) | 19 (12–26) | 23 (16–29) |
| Patella lead (μg/g) | 26 (18–37) | 27 (17–39) | 26 (18–37) | 24 (19–35) | 31 (21–43) |
| Blood lead (μg/dL)b | 5 (4–7) | 5 (4–7) | 5 (4–7) | 5 (3–7) | 5 (4–7.5) |
QTc intervals = QT measured in lead I × √ (heart rate/60).
a
Subjects excluded because of missing genotype data.
b
Reduced numbers of subjects with blood lead for subjects with all three genotypes, 0 gene variants, 1 gene variant, and 2 or 3 gene variants were 599, 232, 267, 100, and 128, respectively.